Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis
- Knaus, Alexej
- Pantel, Jean Tori
- Pendziwiat, Manuela
- Hajjir, Nurulhuda
- Zhao, Max
- Hsieh, Tzung-Chien
- Schubach, Max
- Gurovich, Yaron
- Fleischer, Nicole
- Jäger, Marten
- Köhler, Sebastian
- Muhle, Hiltrud
- Korff, Christian
- Møller, Rikke S
- Bayat, Allan
- Calvas, Patrick
- Chassaing, Nicolas
- Warren, Hannah
- Skinner, Steven
- Louie, Raymond
- Evers, Christina
- Bohn, Marc
- Christen, Hans-Jürgen
- van den Born, Myrthe
- Obersztyn, Ewa
- Charzewska, Agnieszka
- Endziniene, Milda
- Kortüm, Fanny
- Brown, Natasha
- Robinson, Peter N
- Schelhaas, Helenius J
- Weber, Yvonne
- Helbig, Ingo
- Mundlos, Stefan
- Horn, Denise
- Krawitz, Peter M
Publication date
January 2018
DOI Publisher
Springer Science and Business Media LLCAbstract
Glycosylphosphatidylinositol biosynthesis defects (GPIBDs) cause a group of phenotypically overlapping recessive syndromes with intellectual disability, for which pathogenic mutations have been described in 16 genes of the corresponding molecular pathway. An elevated serum activity of alkaline phosphatase (AP), a GPI-linked enzyme, has been used to assign GPIBDs to the phenotypic series of hyperphosphatasia with mental retardation syndrome (HPMRS) and to distinguish them from another subset of GPIBDs, termed multiple congenital anomalies hypotonia seizures syndrome (MCAHS). However, the increasing number of individuals with a GPIBD shows that hyperphosphatasia is a variable feature that is not ideal for a clinical classification
Add to ORKG